Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (181-190 of 211) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II StudyKathleen N Moore, Setsuko K Chambers, Erika P Hamilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2014
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Daniel Morgensztern, Meghan J Campo, Suzanne E Dahlberg, et al.
Cancer Cell|August 26, 2022
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancerMark M Awad, Ramaswamy Govindan, Kristen N Balogh, et al.
Nature Medicine|June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsTimothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerDavid R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.
The New England Journal of Medicine|June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerJulie Brahmer, Karen L Reckamp, Paul Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Pageof 22

Showing results (181-190 of 211) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II StudyKathleen N Moore, Setsuko K Chambers, Erika P Hamilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2014
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Daniel Morgensztern, Meghan J Campo, Suzanne E Dahlberg, et al.
Cancer Cell|August 26, 2022
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancerMark M Awad, Ramaswamy Govindan, Kristen N Balogh, et al.
Nature Medicine|June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsTimothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerDavid R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.
The New England Journal of Medicine|June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerJulie Brahmer, Karen L Reckamp, Paul Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.
Pageof 22